SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Soleno Therapeutics Inc

Soleno Therapeutics is surging following the FDA approval of VYKAT XR, the first treatment for hyperphagia in Prader-Willi syndrome, fueling community discussion around its blockbuster potential and possible future acquisition. Investors are closely monitoring the stock's transition from a clinical-stage development play to a commercial-stage entity, with analysts aggressively revising price targets upward to reflect the de-risked profile.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as traders closely watch the stock's relative strength and consolidation patterns amid a broader market pullback. Market participants are actively discussing the impact of recent subscription price increases on revenue growth while monitoring key technical resistance levels that could trigger a potential breakout.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is currently experiencing intense volatility and downward pressure as investors grow increasingly frustrated with leadership's communication and the lack of a major partnership or buyout announcement. The community is actively debating the impact of recent R&D leadership changes and speculative proxy pressure, while many remain focused on the potential value of the Matrix-M platform to spark a significant recovery.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is maintaining strong momentum as the community rallies around its unique 'culture-first' brand identity ahead of key industry events. Investors are actively discussing its long-term potential, citing consistent organic growth and a commitment to advocacy that resonates with supporters beyond traditional market metrics.

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Neurocrine Biosciences, Inc.

Neurocrine Biosciences is trending due to a definitive agreement to acquire Soleno Therapeutics for $53 per share in an all-cash deal valued at approximately $2.9 billion. Community sentiment is mixed, with some investors debating the valuation and strategic rationale of the acquisition, while others are pressuring management to accelerate pipeline development or consider selling the company to unlock shareholder value.

“Buttcoin - The Next Bitcoin” is the memecoin version of Bitcoin. Launched on January 30, 2025, on Pump.fun, it’s a community-owned memecoin on Solana. The idea was inspired by a 4:20 minutes long YouTube video from 2013 called "The Next Bitcoin?" by James D. McMurray.

The Next Bitcoin

Investors are rallying behind $BUTTCOIN as a satirical movement aimed at disrupting the traditional financial system, with community members actively promoting it as the next major meme cycle. The conversation is driven by intense speculation and viral narratives, with supporters urging others to join the movement to flip Bitcoin while others emphasize the coin's role as a lighthearted commentary on market volatility.

ProShares Trust - ProShares K-1 Free Crude Oil ETF

ProShares K-1 Free Crude Oil Strategy ETF

ProShares K-1 Free Crude Oil Strategy ETF is attracting attention as the broader energy sector faces significant volatility driven by a growing global crude supply glut and shifting geopolitical dynamics, including potential ceasefire developments and diplomatic negotiations. Market participants are actively debating the sustainability of current oil price levels, with many community members focusing on technical indicators, inventory data, and the potential impact of geopolitical cooling on long-standing supply-shock narratives.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the following segments: Materials and Magnetics. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is attracting significant investor attention as defense and technology sectors prioritize domestic rare earth magnet production to secure supply chains against potential geopolitical disruptions. The community is actively discussing the stock's strategic role in national security and potential price catalysts following major government partnership developments.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The crow with knife community is actively buzzing with bullish sentiment, highlighting the token's multichain capabilities and deflationary burn mechanism as key drivers for potential long-term growth. Investors are framing the project as a standout meme coin with a dedicated following, frequently comparing its early-stage potential to other established meme market leaders.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing increased investor attention as a leading example of post-quantum cryptography in a recent Google research paper, bolstering the community's long-term thesis on its security standards. While some users are actively debating potential institutional utility and the impact of the foundation's shift to the U.S., community discussions remain heavily polarized between long-term proponents betting on technical robustness and critics focused on recent price trends.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Brokers Issue Forecasts for ZNTL FY2030 Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Equities research analysts at HC Wainwright issued their FY2030 earnings estimates for Zentalis Pharmaceuticals in a report released on...

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Downgraded by Wall Street Zen to "Sell"

Wall Street Zen cut Zentalis Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday...

Zentalis Pharmaceuticals' (ZNTL) "Buy" Rating Reiterated at Guggenheim

Guggenheim reaffirmed a "buy" rating and issued a $6.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday...

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Posts Earnings Results

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus...

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Rating of "Hold" by Brokerages

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) has received a consensus rating of "Hold" from the six ratings firms that are covering the stock, MarketBeat reports. One research...

Zentalis Pharmaceuticals (ZNTL) to Release Earnings on Wednesday

Zentalis Pharmaceuticals (NASDAQ:ZNTL) will be releasing its Q4 2025 earnings before the market opens on Wednesday, March 25. (View Earnings Report at...

Wells Fargo & Company Initiates Coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Wells Fargo & Company began coverage on Zentalis Pharmaceuticals in a research note on Tuesday. They issued an "equal weight" rating and a $5.00 price objective on the stock...

Zentalis Pharmaceuticals, Inc. $ZNTL Shares Sold by Almitas Capital LLC

Almitas Capital LLC trimmed its position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 71.4% during the third quarter, according to the company in its most recent 13F filing with...

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from Analysts

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) has been assigned an average recommendation of "Hold" from the six research firms that are currently covering the stock, MarketBeat...

Zentalis Pharmaceuticals Details Azenosertib Path to PROC Approval, DENALI Dose Pick Coming Soon

Zentalis Pharmaceuticals (NASDAQ:ZNTL) executives outlined a strategy centered on advancing its WEE1 inhibitor azenosertib toward potential approval in platinum-resistant ovarian cancer (PROC...

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Zentalis Pharmaceuticals Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

ZNTL
Zentalis Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ZNTL News

ZNTLZentalis Pharmaceuticals Inc